Mark Twain once stated that reports of his demise have been greatly exaggerated. The same can be said for how sales of Ozempic and all the other GLP-1’s would impact sales of diabetes tech. We got our first set of facts toady when Abbott reported strong growth for sales of Libre. This really should not come as a surprise as once again we were right, and the analysts were wrong.
We’ll see even more evidence when Dexcom and Insulet report in early November.
Here is the reality of the CGM market a reality that really hasn . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.